MIRAMAR, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for treatments of autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that the Company secured up to $10.0 million in cash to fund the clinical and operating activities necessary to complete the dose-escalating Phase 1 study evaluating HCW9302 as a monotherapy for the treatment of alopecia areata and establishing the Recommended Phase 2 Dose which is expected in the first quarter of 2027.

佛罗里达州米拉马尔，2026年11月5日（环球电讯社）——美国临床阶段生物制药公司、新型多功能融合免疫疗法领先开发商HCW Biologics Inc.（以下简称“公司”或“HCW Biologics”）（纳斯达克股票代码：HCWB），今日宣布，公司已获得高达1,000万美元的现金资金，用于资助完成评估HCW9302作为单一疗法治疗斑秃的剂量递增I期临床研究以及确定推荐II期剂量所需的临床和运营活动，预计该推荐剂量将于2027年第一季度确定。

On November 4, 2026, the Company closed on a debt financing, which provided $3.0 million upon closing and access to $7.0 million in additional funds, subject to certain conditions..

2026年11月4日，公司完成了一笔债务融资，在交割时获得了300万美元，并在满足某些条件的前提下，可获得额外700万美元的资金。

About HCW Biologics:

关于HCW Biologics：

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics for the treatment of diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multivalent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain.

HCW Biologics Inc.（“公司”）（纳斯达克股票代码：HCWB）是一家处于临床阶段的生物制药公司，致力于开发变革性的融合免疫治疗药物，用于治疗由慢性炎症引发的疾病，包括自身免疫性疾病、癌症和衰老相关发育不良。HCW Biologics 在利用独特的蛋白质支架（不含抗体 Fc 结构域）创建多价免疫治疗药物方面处于领先地位。

The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity.

该公司的免疫疗法代表了一类新型药物，公司认为其有望从根本上改变由慢性炎症驱动的促炎性疾病和衰老相关疾病及病症的治疗方式，从而改善患者的生活质量，并可能延长寿命。

A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules.

公司临床开发和融资战略的一个关键方面是专注于其业务发展计划，包括用于生产癌症和传染病免疫治疗药物的商业化就绪试剂。迄今为止，公司已签订两项许可协议，将其部分自有分子的独家全球权利授予他人。

See the Company Pipeline at .

请参阅公司项目管线，网址为 。

https://hcwbiologics.com/pipeline/

https://hcwbiologics.com/pipeline/

Forward Looking Statements:

前瞻性陈述：

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, successfully completing Phase 1 study to evaluate HCW9302 in alopecia areata; timing of a Phase 1 readout for the HCW9302 study in the first quarter of 2027; completing of the dosing of four dose-escalating cohorts by the first quarter of 2027; results of the evaluations of HCW9302 in the Phase 1 study including dose-limiting toxicities; whether the funding secured will be adequate to reach the Phase 1 readout for the HCW9302 study.

本新闻稿中的陈述包含“前瞻性陈述”，这些陈述受重大风险和不确定性的影响。这些陈述是根据美国1995年《私人证券诉讼改革法案》的“安全港”条款作出的。本新闻稿中包含的前瞻性陈述可以通过使用诸如“预期”、“预计”、“相信”、“将”、“可能”、“应该”、“估计”、“预测”、“展望”、“预报”或其他类似词语来识别，并包括：成功完成评估HCW9302治疗斑秃的1期研究；在2027年第一季度公布HCW9302研究的1期结果；在2027年第一季度完成四个剂量递增队列的给药；1期研究中关于HCW9302的评估结果（包括剂量限制性毒性）；所获得的资金是否足以支持实现HCW9302研究的1期结果公布。

Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026 and in other filings filed from time to time with the SEC..

前瞻性陈述基于公司当前的预期，并受限于难以预测的固有不确定性、风险和假设。此外，某些前瞻性陈述基于对未来事件的假设，而这些假设可能被证实并不准确。导致实际结果出现差异的因素包括但不限于公司在2026年3月31日向美国证券交易委员会（“SEC”）提交的10-K表年度报告中“风险因素”一节所述的风险和不确定性，以及公司不时向SEC提交的其他文件中所述的风险和不确定性。

Company Contact:

公司联系人：

Rebecca Byam

丽贝卡·拜厄姆

Chief Financing Officer

首席融资官

HCW Biologics Inc.

HCW 生物制药公司

RebeccaByam@hcwbiologics.com

RebeccaByam@hcwbiologics.com

This press release was published by a CLEAR® Verified individual.

本新闻稿由一位经 CLEAR® 验证的个人发布。